1Food and Drug Control Centre (LFDA), Tripoli, Libya
2Medical Supply Organization (MSO), Tripoli, Libya
3Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya
4Zoology Department, Faculty of Science, Tripoli University, Libya
5Chemical Engineering Department, Faculty of Engineering, Tripoli University, Libya
6Department of Biosciences, University of Salzburg, Salzburg, Austria
*Corresponding author: Ketut Ardhana I, Vice President, University Professor in Asian History, Bali-Indonesia
Submission: October 15, 2021;Published: October 26, 2021
Background and Aim: Vaccines to prevent SARS-CoV-2 infection may be considered a promising way for reduction of the pandemic. Many different vaccines have become obtainable for use in many countries. The present study aims to evaluate the immune response and the safety of Sinopharm COVID-19 vaccine on 14 days old mice.
Materials and Methods: Our experimental study was performed on two weeks old mice, selected by random allocation. The mice were divided into three groups of 12. Group one received a single dose of 0.5ml Sinopharm COVID-19 vaccine, group two received two doses of 0.5ml Sinopharm COVID-19 vaccine, and group three (control) received two doses of 0.5ml of 0.9% NaCl.
Results: Our study shows that Sinopharm COVID-19 vaccine is safe and induces good immunity in young mice.
Conclusion: The Sinopharm COVID-19 vaccine was safe and immunogenic in 14 days old mice. The two doses of Sinopharm COVID-19 vaccine elicit a safe antibody response in young mice. Further post-marketing toxicity studies are required to assess potential hazards for children to evaluate the histopathological characteristics.
Keywords: Sinopharm COVID-19 vaccine; Mice; Coronavirus disease (COVID-19); Immunogenic; Safety